The Biology and Pathology of Your Diagnosis

Understanding the biology of a Metastatic PitNET (pituitary carcinoma) requires looking past the name and into the specific “personality” of the tumor cells. Unlike many other cancers, these tumors aren’t diagnosed by how aggressive the cells look under a microscope, but rather by where they have traveled ^[1].

The Rule of Metastasis

In the world of pituitary tumors, there is a strict technical boundary between an “aggressive” tumor and a “carcinoma” (metastatic PitNET) ^[1][2]:

• Aggressive PitNET: These tumors may grow rapidly, invade nearby structures like the sinuses or bone, and resist standard treatments like surgery or radiation ^[3]. They often have high markers of cell growth ^[3].
• Metastatic PitNET (Carcinoma): This diagnosis is only given when there is proven metastasis—meaning the tumor has spread to the cerebrospinal fluid, the brain/spine, or distant organs like the liver or lungs ^[1][2].

Surprisingly, a tumor can look very “quiet” or “bland” under a microscope and still be a carcinoma if it has spread ^[4]. Conversely, a tumor can look very “angry” or aggressive but is not called a carcinoma if it stays confined to the pituitary area ^[1].

Hormone Subtypes and Your Symptoms

The type of hormone the tumor produces (its “lineage”) largely determines the symptoms you experience. The most common subtypes of metastatic PitNETs include ^[5][6]:

1. ACTH-secreting (Corticotroph): Approximately 35–38% of cases ^[5][6]. These tumors produce ACTH, which tells your adrenal glands to make cortisol. This can lead to Cushing’s syndrome, characterized by rapid weight gain, a “buffalo hump” on the upper back, high blood pressure, and skin that bruises easily ^[7][8]. Note: some corticotroph tumors are “silent,” meaning they are ACTH-lineage but do not cause clinical Cushing’s syndrome.
2. Prolactin-secreting (Lactotroph): Approximately 24–29% of cases ^[5][6]. High levels of prolactin can cause milk production (galactorrhea), and the loss of menstrual periods in women or low testosterone and libido in men ^[9]. Visual changes often occur with these tumors, but they are generally caused by the tumor’s physical mass pressing on the optic nerve, not by the prolactin hormone itself.
3. GH-secreting (Somatotroph): These tumors produce excessive growth hormone, which can lead to acromegaly (enlargement of the hands, feet, and facial features) ^[10].
4. Null-cell and Nonfunctioning: These tumors do not produce significant amounts of active hormones. They are often “silent” until they grow large enough to press on nearby nerves, causing headaches or vision loss ^[3].

Reading Your Pathology Report

Your pathology report uses several markers to estimate how “active” the tumor is. While these inform prognosis and treatment, they are not universal cutoffs that determine spread, and no single value diagnoses metastasis ^[11].

Ki-67 Labeling Index

The Ki-67 index measures the percentage of cells that are currently dividing.

• In many aggressive tumors, a Ki-67 of 10% or higher is associated with faster growth and a higher risk of the tumor spreading sooner ^[12][6].
• However, a low Ki-67 (even below 3%) does not rule out the possibility of future spread ^[4][11]. Some tumors remain stable for years with low markers before suddenly becoming more active ^[10].

Mitotic Count and p53

• Mitotic Count: This counts how many cells are caught in the act of splitting (mitosis) within a specific area. Higher counts (typically 2 or more per 10 high-power fields) suggest more rapid growth, but these thresholds vary by lab and sampling ^[12].
• p53 Expression: The p53 protein helps regulate cell death. If your report shows “overexpression” or “strong staining” of p53, it may indicate cellular changes, but it is not interpreted identically by every lab and is not absolute proof that the tumor has lost all growth control ^[12].

Molecular Markers: MGMT

You may see a test for MGMT (O6-methylguanine-DNA methyltransferase) on your report. This protein can actually “repair” the DNA damage caused by certain chemotherapies, such as Temozolomide ^[13].

• In theory, a tumor with low MGMT (or “methylated” MGMT promoter) should respond better to chemotherapy because it cannot repair itself ^[13].
• The Limitation: In practice, MGMT testing (especially protein immunostaining) is not standardized enough to be perfectly reliable for pituitary tumors. Some patients with high MGMT levels still respond to treatment, and some with low levels do not ^[13][14]. Because of this, doctors usually do not use MGMT results alone to decide whether or not to try chemotherapy ^[15].

Current guidelines suggest that the clinical response (how you feel and what the scans show after a few months of treatment) is a much better guide than the MGMT test alone ^[15].